Specifically, NICE’s recommendation is extended to patients with untreated HER2-negative, advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma if the tumours express PD-L1 with a combined positive score (CPS) of five or more. Around 3,000 people could be eligible for the new combination therapy.
Opdivo is a targeted immunotherapy designed to recognise and attach to a specific protein called programmed death-1 receptor (PD-1), which can shut off the body’s immune system. By attaching to PD-1, Opdivo blocks its action and allows the body’s immune system to continue to attack the gastric, oesophageal or gastro-oesophageal junction cancer cells…
